Northwest Savings Bank

Northwest Biotherapeutics is a clinical-stage biotechnology company focused on developing personalized immunotherapy products for the treatment of solid tumor cancers. The company's lead product, DCVax-L, is a dendritic cell-based vaccine that has completed a large Phase 3 clinical trial for newly diagnosed and recurrent glioblastoma multiforme (GBM), demonstrating significant improvements in overall survival. Its proprietary DCVax technology platform utilizes a patient's own dendritic cells to trigger a broad immune response against the full range of antigens present in their specific tumor. In addition to GBM, the company is exploring the application of its technology in other solid tumors through its DCVax-Direct program, which is currently in Phase 1/2 development. The company operates primarily in North America and Europe, utilizing specialized manufacturing partnerships to produce its individualized therapies.